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(1.58 vs. 0.36, p0.01), physician (10.17 vs.8.96, p0.01) and ED visits (1.12 vs. 0.67,
p0.01) than NoRxOP patients in the follow-up period. RxOP users had twice the
total healthcare costs ($49,766 vs. $19,875, p0.01) than NoRxOp patients.
CONCLUSIONS: A large percentage of patients are prescribed opioids for the first
time during ED/inpatient visits and incur a significantly higher resource use and
economic burden than those who are not.
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OBJECTIVES: Schizophrenia and bipolar disorder (BD) are psychiatric disorders
that are associated with a substantial clinical and economic burden. Hospitaliza-
tion and in-patient care commonly account for a large proportion of medical costs
in these illnesses. A secondary objective of the Italian Burden of Illness on Schizo-
phrenia and BD (IBIS) study is to assess any differences in terms of cost of illness for
patients with schizophrenia and BD switching from QTP-IR to QTP-XR.METHODS:
Multicenter, retrospective, observational, real world cohort study (NCT01392482).
The data shown are interim results collected from administrative databases in 6 of
20 Italian Local Health Units included in the study. Data were collected between 1
January 2009 and 31 December 2010. Patients that switched fromQTP-IR to QTP-XR
were included for analysis. Data were collected 6 months before (IR period) and 6
months after (XR period) the switch. RESULTS: In total, 213 patients switched
medication from QTP-IR to QTP-XR (86 with schizophrenia, 127 with BD). For pa-
tients with schizophrenia, disease-related costs per patient totaled €4123 during
the IR period and €3832 during the XR period, indicating a decrease of 7%. Although
hospitalization costs per patient remained similar after the switch (IR period:
€1111, 26.9% of total costs; XR period: €998, 26.0% of total costs), care/nursing home
costs decreased in the XR period (IR period: €1906, 46.2% of total costs; XR period:
€1330, 34.7% of total costs). For patients with BD, disease-related costs per patient
decreased by 23%, from €3877 during the IR period to €2,973 during the XR period.
Hospitalization costs per patient fell substantially after the switch (IR period: €2659,
68.6% of total costs; XR period: €1,171, 39.4% of total costs). CONCLUSIONS: These
interim results suggest that switching from QTP-IR to QTP-XR decreases direct
health care costs and in-patient resource use.
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OBJECTIVES: To assess the cost-consequences of cardiometabolic effects of lurasi-
done versus other atypical antipsychotics in adults with schizophrenia and com-
pare the results based on published cardiovascular and diabetes risk equations
from the Framingham Heart Study (FHS), the Atherosclerosis Risk in Communities
study (ARIC), and the San Antonio Heart Study (SAHS).METHODS: A discrete event
simulation model was developed to simulate the economic outcomes based on
cardiometabolic parameter changes after 1-year treatment. With a 3-year time
horizon, the model predicted the number of: 1) incident diabetes cases using each
of the risk equations, and 2) cardiovascular events (e.g., coronary heart disease
(CHD), stroke) (CVD) based on updated cardiometabolic values at 1 year, and esti-
mated the costs associated with each event. Data were drawn from comparative
clinical trials of lurasidone for lurasidone, risperidone, and quetiapine, and from
the literature for olanzapine. Cost data in 2011 values were obtained from public
data sources and discounted at 3.5% annually. RESULTS: Compared with olanzap-
ine, risperidone, and quetiapine, lurasidone: 1) avoided 119, 15, and 7 diabetes
cases and saved $1708, $192, and $95 per patient, excluding the costs of antipsy-
chotics and other events, respectively, when using FHS equation; 2) avoided 58, 8,
and 0 diabetes cases and saved $1,036, $114, and $22 when using SAHS equation;
and 3) avoided 52, 7, and 7 diabetes cases and saved $900, $76, and $88 when using
ARIC equation. Incidence of other CVD eventswas low across all drugs in themodel
due to the short time-horizon. Lurasidone saved$9600 per patient in all compar-
isons when costs of other CVD events and antipsychotics were included.
CONCLUSIONS: In this analysis, lurasidone was a cost-saving option compared to
other antipsychotics. Although the magnitude of cost savings with lurasidone dif-
fered based on the risk equation used, cost savings with lurasidone were consis-
tently observed.
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OBJECTIVES: The aim of this study is to assess the health system and patient costs
associated with antidepressant (AD) use considering the presence and persistence
of depression and anxiety. METHODS: The data was retained from a population-
based health survey on 2004 community dwelling older adults aged  65 years
participating in the ESA (Étude sur la Santé des Aînés) study. Depression and anx-
iety were assessed using DSM-IV criteria and measured at 2 time points one year
apart. Medical and non-medical costs were considered. Medication and health
service use and costs were identified from provincial administrative databases.
The excess costs associated with AD use as a function of mental health status was
analysed using generalized linear models with a gamma distribution (log link),
controlling for a number of factors.RESULTS:The prevalence of antidepressant use
reached 15.5%: SSRIs followed by TCAs were the most common. Significantly
higher health care costs (	: $2840, Wald 260.00, df1, p0.0001) were associated
with ADuse. Among antidepressant users, the results did not show any differences
in costs when accounting for dosage, the number of episodes of use and the pres-
ence of antidepressant switches. Among persistent cases of depression and anxi-
ety the use of AD was associated with lower adjusted total costs reaching CDN
$2724 and CDN $2114, respectively. The use of AD can result in cost savings reach-
ing $154.6 million and $118.4 million per 1 000 000 population, for persistent cases
of depression and anxiety. CONCLUSIONS: This study showed important cost sav-
ings associated with AD use in persistent cases of depression and anxiety. Future
studies should focus on further exploring potential cost savings associated with
different classes of AD in the treatment of different clinical profiles of depression
and anxiety and this in the older adult population.
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OBJECTIVES: The objective of this study was to identify the demographic and clin-
ical characteristics of schizophrenia patients who experience high schizophrenia-
related directmedical costs.METHODS: Patientswith a diagnosis for schizophrenic
disorder (ICD-9-CM code 295) and other non-organic psychoses (ICD-9-CM code
298) were identified from the 2005-2008 Medical Expenditure Panel Survey (MEPS),
a national representative annual survey of non-institutionalized US residents.
Schizophrenia-related direct medical costs were calculated for the following utili-
zation categories: inpatient hospitalizations, prescriptionmedications, and outpa-
tient, office-based physician, emergency department, and home healthcare visits.
Based on the distribution of their total costs, patients were classified into high-cost
(expenditures$16,000) and low-cost (expenditures$16,000) groups. Logistic re-
gression was used to determine the likelihood of high-cost group membership
based on patient demographic and clinical characteristics. Generalized Linear
Models (GLM) regression was used to evaluate the relationships between the inde-
pendent variables and costs. RESULTS: There were 317 patients (weighted fre-
quency2.75 million) with schizophrenia-related costs. Based on the logistic re-
gression procedure, it was seen that older patients were less likely to be in the
high-cost group; for each one-year increase in age, patients were 6.4% less likely to
have high costs (odds ratio [OR]0.936). Patients with a spouse were 83.0% less
likely than those without a spouse to be in the high-cost group (OR0.170). The
GLM regression procedure showed that age, race, and region of residence were
significantly associated with costs. On controlling for other factors, with a one year
increase in age, costs decreased by $127 (p0.001), Caucasians spent $3,831
(p0.019) less than African Americans, and patients living in Southern US spent
$3,718 (p0.01) less than those living in the Northeast. CONCLUSIONS: Identifying
the high-risk population may help policy makers allocate resources more effi-
ciently andhealth care providersmanage patientsmore effectively through assign-
ment of high-risk patients to casemanagers and appropriatemonitoring and treat-
ment.
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OBJECTIVES: To estimate the schizophrenia-related direct medical costs using the
attributable and incremental cost approaches.METHODS: Patients with a diagno-
sis for schizophrenic disorder (ICD-9-CM code 295) and other non-organic psycho-
ses (ICD-9-CM code 298) were identified from the 2005-2008 Medical Expenditure
Panel Survey (MEPS), a nationally representative annual dataset of non-institution-
alized US residents. Schizophrenia-related direct medical costs were estimated for
inpatient hospitalizations, prescription medications, and outpatient, office-based
physician, emergency department, and homehealthcare visits, and overall. For the
attributable cost approach, schizophrenia-related costs were identified from each
of theMEPS event files. For the incremental cost approach, the differences between
the costs for patients with and without schizophrenia for each service type were
calculated to yield the schizophrenia-associated incremental costs. RESULTS:We
identified 348 patients with schizophrenia (weighted frequency3.03 million). The
mean schizophrenia-related direct medical cost per patient-year using the attrib-
utable cost approach was $5,538 (SE$570). With the incremental cost approach,
themean cost per patient-year was $12,369 (SE$1,205) for schizophrenia patients
and $3,198 (SE$47) for non-schizophrenia patients. Thus, the incremental cost
associated with schizophrenia was $9171 (SE1207) per patient-year. When demo-
graphic and clinical factors such as age, sex, race, marital status, insurance status,
socioeconomic status, region of residence, perceived health status, mental health
status, number of medical comorbidities, and number of mental health-related
comorbidities were controlled for using ordinary least squares regression, the
mean schizophrenia-related incremental direct medical cost per patient-year was
$5115 (SE$1240). CONCLUSIONS: This study highlights the high financial burden
of schizophrenia. Although the mean cost per patient-year estimated using the
incremental cost approach was higher than that obtained using the attributable
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cost approach, the estimates were similar when patient demographic and clinical
characteristics were controlled for in the incremental cost approach.
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OBJECTIVES: Depression is a major health problem. Previous studies on the cost of
depression have mainly taken a primary care perspective. Such studies do not
include all patients with depression, and should be completed by cost estimates
from psychiatric care. The objectives of this study were to estimate the annual
societal cost of depression per patient in psychiatric care in Sweden, and to relate
costs to disease severity, depressive episodes, hospitalization, and patient
functioning. METHODS: Retrospective resource use data in inpatient and outpa-
tient care for 2006-2008, as well as ICD-10 diagnoses and Global Assessment of
Functioning (GAF), were obtained fromNorthern Stockholm psychiatric clinic with
a catchment area including 47% of the adult inhabitants in Stockholm city. This
data setwas combinedwith national register data on prescription pharmaceuticals
and sick leave to estimate the societal cost of depression. RESULTS: The study
included 10,593 patients (63%women). The average annual societal cost per patient
was aroundUSD 21,000 in 2006-2008. The largest cost itemwas indirect costs due to
productivity losses (89%), and the second largest was outpatient care (6%). Patients
with mild, moderate or severe depression had an average cost of approximately
USD 18,000, USD 21,000, andUSD 29,000, respectively. Total costswere significantly
higher during depressive episodes, for patients with co-morbid psychosis or anxi-
ety, for hospitalized patients, and for patientswith lowGAF scores.CONCLUSIONS:
The largest share of societal costs for patientswith depression in psychiatric care is
indirect. The total costs were higher than previously reported from a primary care
setting, and strongly related to hospitalization, episodes of active depression, and
global functioning. This suggests that effective treatment and rehabilitation that
avoid depressive episodes and hospitalization may not only improve patient
health, but also reduce the societal cost of depression.
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OBJECTIVES: Estimate the cost of a psychiatric relapse in the Brazilian private
healthcare system. METHODS: Using a claims database, 842 patients were classi-
fied according to one of the following diagnoses: organic delusional disorder
(schizophrenia-like), schizophrenia, schizotypal disorder, persistent delusional
disorder or schizoaffective disorder. During 26 months, from August/2009 to Sep-
tember/2011, all patients that first used the private healthcare system were ana-
lyzed and followed. All costs associated with the treatment of schizophrenia were
considered across seven major categories: hospitalization, medications, proce-
dures, materials, exams, alimentation and hygiene care. RESULTS: Out of the 842
patients that used the private health care system in a period of 26 months, 388
returned to the hospital (“return patients”, 46%) and accounted for 85% (R$
8,800,518.79) of the costs during the period of the analysis. The majority of the
“return patients”, 57% (n221), were re-hospitalized between 2 and 4 times, and 9%
(n35) returned 20 times or more during the period studied. “Return patients”
presented an average total cost of R$ 22,681.75/patient in 26 months, a cost per
patientmore than 6 times higherwhen comparedwith those that did not return (R$
3,511.72/patient/26 months). Most costs were accountable to hospitalization (75%),
followed by medication (14%). The most frequently used medications by the 842
patients, in units, in decreasing order were: levomepromazine, haloperidol and
clonazepam. CONCLUSIONS: Although patients with hospitalizations represented
46% of the sample, they accounted for 85% of the costs occurred in the 2 year
period. As a result, avoiding hospitalization in psychiatric relapse could be an
effective cost-saving investment. Furthermore, the claims database does not con-
sider all outpatient costs incurred by the sample, so these results might be under-
estimated.
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IMPACT OF SECOND GENERATION ANTI-PSYCHOTICS IN BIPOLAR PATIENTS
AND SCHIZOPHRENIA PATIENTS IN TH CALIFORNIA MEDICAID PROGRAM
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OBJECTIVES:Compare the health care utilization achieved by patientswith schizo-
phrenia and bipolar disorder using atypical and typical antipsychotics.METHODS:
Episodes of antipsychotic therapy were identified using data from California Med-
icaid program from 1994 to 2003. The first observed episode for each patient was
then excluded leaving four types of episodes: restarting therapy using the same
drug as the preceding episodes after a discontinuation; switching therapy using a
different drug after a break in treatment; switching therapy without a break in
treatment, and augmentation. A propensity score model of atypical antipsychotic
use was estimated using drug therapy episodes between Oct 1997, the first month
that the atypical antipsychotics were available without restrictions, and Dec 2002.
A total of 296,284 episodes of atypical antipsychotic therapy were matched with
typical antipsychotic drug therapy identified using all restart, switching and aug-
mentation episodes identified in the period 1994-2003. The impact of atypical an-
tipsychotic use on health care utilization patterns over a one-year post-treatment
period were analyzed using OLS regressions. RESULTS: Atypical antipsychotic use
increased total one year post-treatment cost by $583 dollars (p0.0001) for restart
episodes, $1620 dollars for delayed switch episodes (p0.0001) and$1318 dollars
(p0.0001) for switch episodes. The use of atypical antipsychotics was not associ-
ated with any statistically significant change in total cost for augmentation epi-
sodes. For all four types of episodes, using atypical antipsychotics was associated
with significantly higher one year post-treatment drug costs ($375 to $1413) which
were partially offset by significant reductions inmedical costs for switching, restart
and augmentation episodes. Using atypical antipsychotics reduced acute hospital
admission but hadmixed effects on psychiatric hospital and nursing home admis-
sion across episode types. CONCLUSIONS: There is some evidence that the in-
creased drug costs associated with atypical antipsychotics use are partially offset
by decreased costs of other medical services.
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OBJECTIVES: The aim of the present study was to conduct an economic evaluation
comparing Agomelatine with its most common alternatives in daily clinical prac-
tice for treating patients with Major depressive disorder (MDD) in Greece.
METHODS: An existing Markov model evaluating the 2-year cost-effectiveness of
Agomelatinewas adapted to the Greek setting. Themodel consists of six states and
the cycle length was set to one month. The analysis was conducted by the Greek
societal perspective. Input data (i.e. transition probabilities, costs assigned to each
health state, utility values and probabilities for adverse events) were obtained from
published literature, government sources, and experts’ opinion. Head-to-head
clinical trials of Agomelatine versus active comparators (if available) were used,
and indirect comparisons were conducted in the absence of directly comparative
trials. Both direct and indirect costswere considered in themodel. The resultswere
expressed as incremental cost-effectiveness ratios (ICERs) per quality-adjusted-
life-year (QALY) gained. RESULTS: The Markov model revealed that the average
total cost related to 2-year treatment of MDDwith Agomelatine is lower compared
to Venlafaxine (€43), Sertraline (€257), Escitalopram (€57) and Fluoxetine (€174) and
higher compared to Mirtazapine (€304) and Citalopram (€217). Moreover, the aver-
age QALYs for Agomelatine-treated patients was found to be higher against all
comparators. In particular, the increment in QALYs varies between 0.015 and 0.088
against Escitalopram and Mirtazapine, respectively. Therefore, Agomelatine is
dominant against all comparators with the exception of Mirtazapine and Citalo-
pram where it is cost-effective (ICER: €26,662/QALY and €11,055/QALY gained, re-
spectively). The probabilistic sensitivity analysis revealed that Agomealtine is cost-
effective against all comparators with a probability between 48.9% and 97% at a
willingness-to-pay threshold of €50,000/QALY gained. CONCLUSIONS: Using con-
servative assumptions, the present economic evaluation indicates that Agomela-
tine may be a more efficient therapy compared to its alternatives for the manage-
ment of patients in Greece.
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OBJECTIVES: To evaluate long-term cost-effectiveness (including hospitalizations
and cardiometabolic consequences) of atypical antipsychotics (AAPs) among
adults with schizophrenia. METHODS: A 5-year Markov cohort cost-effectiveness
model, from a US payer perspective, was developed to compare lurasidone, gener-
ic-olanzapine, aripiprazole, quetiapine, and ziprasidone. Health states included in
the model were: patients on initial AAP; patients switched to a second AAP; and
patients on clozapine after failing a second AAP. Incremental cost-effectiveness
ratios (ICERs) assessed incremental cost/hospitalization avoided. Effectiveness in-
puts included discontinuations, hospitalizations, weight change, and cholesterol
change from comparative clinical trials for lurasidone and for aripiprazole, and
CATIE for other comparators. AAP-specific relative risk of diabetes obtained from a
retrospective analysiswas used to predict cardiometabolic events per the Framing-
ham BMI risk equation. Mental health costs (relapsing versus non-relapsing pa-
tients) and medical costs associated with cardiometabolic consequences (cardio-
vascular events and diabetesmanagement) were obtained frompublished sources.
AAP costs were estimated from Redbook prices at dose(s) reported in the clinical
data sources used in the model (e.g., weighted average dose of lurasidone and
average dose for all other comparators). Costs and outcomes were discounted at
3%, and model robustness was tested using one-way and probabilistic sensitivity
analyses. RESULTS: In a 5-year period, lurasidone dominated ziprasidone, quetia-
pine, and aripiprazole in terms of incremental cost/hospitalization avoided. Com-
pared with generic-olanzapine ($106,407 and 0.424 hospitalizations), lurasidone
patients had an ICER of $16,522/hospitalization avoided ($107,219 and 0.374 hospi-
talizations). Lurasidone had an 89.5% probability of being cost-effective compared
with generic-olanzapine at a willingness-to-pay of $50,000/hospitalization
avoided. One-way sensitivity analysis showed the model is sensitive to hospital-
ization rates and AAP costs. CONCLUSIONS:Model results show that among adults
with schizophrenia, lurasidone is cheaper and more effective versus ziprasidone,
quetiapine, and aripiprazole, and would be cost-effective compared with generic-
olanzapine, due to differences in hospitalization rates and cardiometabolic profile.
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